Real-world treatment costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA

Madduri D, Hagiwara M, Parikh K, Pelletier C, Delea TE, Kee A, Chari A. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol 2021;17(5):503-15.

Abstract and paper first published: https://pubmed.ncbi.nlm.nih.gov/33522834/

 

Background

To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients.

 

Methods

Eligible patients had ≥1 line of therapy (LOT) each of proteasome inhibitors, immunomodulatory drugs, and daratumumab in December 2015-September 2018 and received a new LOT.

 

Results

A total of 154 patients were included with a median follow-up of 6.2 months. Median time from diagnosis to new LOT was 41.0 months. Kaplan–Meier estimate of median time to therapy discontinuation was 4.2 months. Mean per-patient, per-month MM-related costs were USD 35,657. Most frequently observed regimens were lenalidomide or pomalidomide + daratumumab (18.2%), lenalidomide or pomalidomide + proteasome inhibitors (15.6%), and lenalidomide or pomalidomide monotherapy (11.0%).

 

Conclusion

Triple-class exposed RRMM patients receive heterogeneous treatments for a short duration with high healthcare resource utilization and costs.

Read more: https://pubmed.ncbi.nlm.nih.gov/33522834/